Published in Am J Clin Oncol on August 01, 2015
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med (2007) 6.84
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet (2012) 6.65
Modelling Myc inhibition as a cancer therapy. Nature (2008) 5.81
Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet (2012) 4.84
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med (2013) 4.74
The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist (2010) 4.68
Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 4.41
Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA (2011) 4.11
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology (2010) 3.98
Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol (2007) 3.17
Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet (2012) 3.14
Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer (2013) 2.87
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology (2011) 2.66
Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer (2012) 2.49
Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res (1975) 2.49
Prediction of posthepatectomy recurrence of hepatocellular carcinoma by circulating cancer stem cells: a prospective study. Ann Surg (2011) 2.38
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology (2013) 2.37
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res (2013) 2.12
New therapies for hepatocellular carcinoma. Oncogene (2006) 2.05
Aflatoxin B1 induces the transversion of G-->T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A (1993) 1.95
Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol (2009) 1.92
Local-regional treatment of hepatocellular carcinoma. Radiology (2012) 1.78
Screening for hepatocellular carcinoma. Hepatology (1998) 1.78
Serum markers of hepatocellular carcinoma. Dig Dis Sci (2010) 1.76
Expression and prognostic roles of beta-catenin in hepatocellular carcinoma: correlation with tumor progression and postoperative survival. Clin Cancer Res (2002) 1.53
Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl (2005) 1.47
Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J Vasc Interv Radiol (2007) 1.42
Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol (2010) 1.40
Introduction: The burden of hepatocellular carcinoma. Gastroenterology (2004) 1.19
Isolation of circulating tumor cells in patients with hepatocellular carcinoma using a novel cell separation strategy. Clin Cancer Res (2011) 1.14
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs (2010) 1.07
Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Cancer Lett (2012) 1.05
Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Oncogene (2012) 0.92
Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade. Int Surg (2010) 0.87
Barriers to drug delivery in interventional oncology. J Vasc Interv Radiol (2013) 0.86
Capturing circulating tumor cells of hepatocellular carcinoma. Cancer Lett (2012) 0.85
Hepatocellular carcinoma in cirrhotic patients: prospective comparison of US, CT and MR imaging. Eur Radiol (2012) 0.85
TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis. Hepatobiliary Surg Nutr (2013) 0.85
Dysregulation of signaling pathways and putative biomarkers in liver cancer stem cells (Review). Oncol Rep (2012) 0.84
FDG PET/CT and enhanced CT imaging of tumor heterogeneity in hepatocellular carcinoma: imaging-pathologic correlation. Clin Nucl Med (2014) 0.81
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol (2009) 4.17
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Hepatocellular carcinoma: the need for progress. J Clin Oncol (2005) 3.11
Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist (2011) 3.05
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg (2015) 2.79
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res (2008) 2.71
Engaging our patients: shared decision making and interventional radiology. Radiology (2014) 2.53
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol (2007) 2.33
Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer (2009) 2.19
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Bilateral inferior petrosal sinus sampling with desmopressin. J Neurointerv Surg (2012) 2.00
Systemic therapy for biliary tract cancers. Oncologist (2008) 1.98
Advanced hepatocellular carcinoma: CT perfusion of liver and tumor tissue--initial experience. Radiology (2007) 1.87
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol (2006) 1.86
Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res (2012) 1.83
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist (2013) 1.76
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res (2010) 1.71
Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol (2010) 1.69
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J Clin Oncol (2006) 1.64
A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol (2008) 1.64
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology (2009) 1.63
Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology (2010) 1.48
Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res (2013) 1.39
Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer (2011) 1.36
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res (2014) 1.33
Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST). Invest Radiol (2012) 1.33
Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg (2005) 1.30
Intrahepatic cholangiocarcinoma. Surg Clin North Am (2010) 1.27
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther (2009) 1.26
Gemcitabine-associated thrombotic microangiopathy. Cancer (2004) 1.26
Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol (2011) 1.22
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer (2011) 1.20
Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology (2014) 1.16
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci (2007) 1.15
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist (2009) 1.14
A prospective phase II study of 2-methoxyestradiol administered in combination with bevacizumab in patients with metastatic carcinoid tumors. Cancer Chemother Pharmacol (2010) 1.11
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology (2015) 1.11
Response. Radiology (2015) 1.11
May-Thurner syndrome: diagnosis and management. Vasa (2013) 1.11
A nomogram to predict long-term survival after resection for intrahepatic cholangiocarcinoma: an Eastern and Western experience. JAMA Surg (2014) 1.11
Cholangiocarcinoma: current and novel imaging techniques. Radiographics (2008) 1.09
A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors. Dig Dis Sci (2006) 1.09
Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist (2009) 1.09
Measurements of the left common iliac vein diameter may not be consistent over time. J Vasc Interv Radiol (2013) 1.08
Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol (2013) 1.05
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One (2012) 1.05
Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol (2012) 1.03
Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl (2004) 1.02
MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin Cancer Res (2008) 1.01
Role of preoperative angiography in colon interposition surgery. Diagn Interv Radiol (2012) 1.00
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. Oncologist (2011) 0.98
Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer (2014) 0.98
Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy. J Hematol Oncol (2013) 0.97
ALK molecular phenotype in non-small cell lung cancer: CT radiogenomic characterization. Radiology (2014) 0.97
Recurrence after operative management of intrahepatic cholangiocarcinoma. Surgery (2013) 0.96
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 6-2005. A 58-year-old man with esophageal cancer and nausea, vomiting, and intractable hiccups. N Engl J Med (2005) 0.96
Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol (2007) 0.95
May-Thurner syndrome: can it be diagnosed by a single MR venography study? Diagn Interv Radiol (2012) 0.95
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer (2006) 0.95
Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw (2014) 0.93
Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci (2012) 0.92
The medical device excise tax--before it begins? N Engl J Med (2013) 0.92
Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Cardiovasc Intervent Radiol (2013) 0.92
A multicenter retrospective study on clinical characteristics, treatment patterns, and outcome in elderly patients with hepatocellular carcinoma. Oncologist (2011) 0.91
Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs (2009) 0.89
Prospective trial with optical molecular imaging for percutaneous interventions in focal hepatic lesions. Radiology (2014) 0.88
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis. J Hematol Oncol (2009) 0.87
Irreversible electroporation: evolution of a laboratory technique in interventional oncology. Diagn Interv Radiol (2014) 0.87
Barriers to drug delivery in interventional oncology. J Vasc Interv Radiol (2013) 0.86
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer (2006) 0.85
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer (2013) 0.84
Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma. Gastrointest Cancer Res (2011) 0.84
9-cis-Retinoic acid inhibition of lung carcinogenesis in the A/J mouse model is accompanied by increased expression of RAR-beta but no change in cyclooxygenase-2. Cancer Lett (2006) 0.84
Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma. Oncology (2012) 0.83
Multicenter phase II study of tivozanib (AV-951) and everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. Oncologist (2013) 0.83
Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. J Gastrointest Cancer (2014) 0.83
Bilateral inferior petrosal sinus sampling. J Neurointerv Surg (2011) 0.82
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer. Clin Cancer Res (2003) 0.82
Circulating tumor cells: personalized medicine in interventional oncology? J Vasc Interv Radiol (2012) 0.81
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol (2007) 0.81
Ligation of the jugular veins does not result in brain inflammation or demyelination in mice. PLoS One (2012) 0.81
A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Invest New Drugs (2014) 0.81
Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: one step forward? J Clin Oncol (2012) 0.80
Cushing proximal symphalangism and the NOG and GDF5 genes. Pediatr Radiol (2007) 0.80
Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation. JAMA (2008) 0.80
Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors. Endocr Relat Cancer (2012) 0.80
Fractal analysis of contrast-enhanced CT images to predict survival of patients with hepatocellular carcinoma treated with sunitinib. Dig Dis Sci (2014) 0.80
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 0.80
Kidney and Liver Injuries After Major Burns in Rats Are Prevented by Resolvin D2. Crit Care Med (2016) 0.80
Efficacy of lower-extremity venous thrombolysis in the setting of congenital absence or atresia of the inferior vena cava. Cardiovasc Intervent Radiol (2011) 0.80
Microsatellite instability in gallbladder carcinoma. Virchows Arch (2015) 0.80
Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma? Diagn Interv Radiol (2015) 0.79
Poly-ADP-ribose-polymerase inhibition ameliorates hind limb ischemia reperfusion injury in a murine model of type 2 diabetes. Ann Surg (2013) 0.79
Phase II study of pemetrexed in patients with advanced neuroendocrine tumors. Cancer Chemother Pharmacol (2010) 0.79
Catheter-directed thrombolysis of arterial thrombosis. Semin Thromb Hemost (2013) 0.78